Arrowhead Research Corporation ARWR, a targeted therapeutics company,
today announced that it received a Notice of Allowance from the U.S. Patent
and Trademark Office (USPTO) for patent application U.S. 13/032,029 entitled,
“Compositions for Targeted Delivery of siRNA.” The patent broadly covers
compositions, methods, and uses for a new formulation of Arrowhead's Dynamic
Polyconjugate (DPC) siRNA delivery platform, where attachment of siRNA and
delivery vehicle is not required to produce high-level, efficient knockdown of
target genes. The new IP expands the DPC platform and is used in Arrowhead's
ARC-520 candidate in development for chronic hepatitis B virus (HBV)
infection.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in